LONDON, October 14, 2016 /PRNewswire/ --
New easy-to-use
software designed to improve the planning
of 90Y selective internal radiation
therapy (SIRT) treatment for patients with
liver cancer
BTG plc (LSE: BTG), an international specialist
healthcare company, with Mirada Medical Ltd, a leading global brand
in medical imaging software, today announced CE Mark certification
for Simplicit90Y™ dosimetry software, designed to
optimise the planning of 90Y selective internal
radiation therapy (SIRT) and facilitate personalised treatment for
patients with liver cancer. CE Mark certification follows approval
for Simplicit90Y™ in Canada.
(Logo:
http://photos.prnewswire.com/prnh/20160203/329110LOGO )
BTG, in collaboration with Mirada Medical, have developed
Simplicit90Y™ to be a customised, easy-to-use, dosimetry
software developed for rapid 90Y SIRT workflow.
Simplicit90Y™ provides digital processing, review and
reporting of medical images with unique options for data display,
quality control, image manipulation and quantification analysis.
Together, these features allow for more standardised and consistent
dosimetry planning and post-treatment validation, and the ability
to personalise treatment for each patient.
"Simplicit90Y™ represents an important advance in
providing patients and healthcare providers with added value beyond
our products and we are pleased it has received CE Mark
certification," commented Zillah Moore, Director Commercial
Operations EMEA. "It will ensure 90Y therapies, such as
TheraSphere®, can be specifically tailored to individual
patient needs, facilitating personalised treatments.
Simplicit90Y™ will help us offer interventional oncology
teams more power to personalise and optimise 90Y SIRT
for their patients. We're delighted Simplicit90Y™ is now
available for physicians to use."
"Dosimetry can be a time intensive and complex process and
Simplicit90Y™ simplifies both dosimetry planning and
post-treatment validation," said Etienne
Garin, MD, PhD, Chair professor of Nuclear Medicine, Cancer
Institute, Centre Eugene Marquis Rennes, France. "Knowing you can use this intuitive
software to help deliver a more personalised treatment for each
patient, achieving the best dose of 90Y radiation to the
tumour while minimising exposure to healthy tissue, gives
physicians more confidence."
Matthieu Leclerc-Chalvet, Mirada Medical, Managing Director
commented, "We designed this software to simplify the dosimetry
workflow for SIRT and enhance consistency and efficiency. Mirada
Medical supports 90Y treatment quality by incorporating
advanced image processing tools that facilitate the clinician's use
of multi-modal images to plan 90Y SIRT treatment.
Leveraging combined expertise from across the industry helped meet
both the physician's and patient's needs and
Simplicit90Y™ is a clear demonstration of that
success."
BTG and Mirada Medical will be at the 29th Annual EANM Congress
in Barcelona, Spain, 15th - 19th
of October, 2016. Information regarding Simplicit90Y™
will be available via the BTG booth (#62 & 76) and Mirada
Medical booth (#65 & 66) in the main exhibition hall. For more
information on Simplicit90Y™ please visit
http://www.btg-im.com/Simplicit90Y and register your interest.
About
Simplicit90YTM
Simplicit90YTM is a standalone software
device intended for use by Nuclear Medicine (NM) or Radiology
practitioners for display, processing and reporting of data,
including planar scans (Static, Whole Body) and tomographic scans
acquired by gamma cameras or PET scanners. Physicians can use the
system for viewing and assessing image data for general clinical
diagnostic purposes with additional features and optimised workflow
for yttrium-90 (90Y) dosimetry.
About TheraSphere®
TheraSphere® 90Y glass microspheres are
specifically engineered to carry far greater power than any other
90Y liver-directed cancer therapy.
TheraSphere® works predominantly through radiation, with
minimal embolic effect[1] which
allows the microspheres to lodge deeper inside the tumor, achieving
a high absorbed dose. The result is a powerful, targeted and
well-tolerated therapy that may lead to patients becoming eligible
for curative therapies.
In the EU, Singapore,
South Korea and Canada, TheraSphere® is approved
for the treatment of hepatic neoplasia. TheraSphere® is
commercially available in Hong
Kong and Malaysia. In the
US, TheraSphere® is approved under a Humanitarian Device
Exemption (HDE) for use in radiation treatment or as a neoadjuvant
to surgery or transplantation in patients with unresectable
hepatocellular carcinoma (HCC) who can have placement of
appropriately positioned hepatic arterial catheters.
TheraSphere® is also indicated for HCC patients with
partial or branch portal vein thrombosis/occlusion, when clinical
evaluation warrants the treatment. The effectiveness of
TheraSphere® for this use in the US has not been
demonstrated. For full instructions for use and important safety
information, please visit http://www.therasphere.com.
About BTG Interventional Medicine
BTG Interventional Medicine is part of BTG plc, a growing
international specialist healthcare company. As medicine moves from
major surgery to minor procedure, from the systemic to the local,
no company endeavors to do more than BTG Interventional Medicine to
help doctors in their quest to see more, reach further and treat
smarter. Our growing portfolio of Interventional Medicine products
is designed to advance the treatment of cancer tumors, advanced
emphysema, severe blood clots, and varicose veins. To learn more
about BTG Interventional Medicine, please visit:
http://www.btg-im.com.
About Mirada Medical Ltd
Mirada Medical is a leading international brand in medical
imaging. The company develops advanced software applications which
help healthcare professionals use medical images more effectively
and efficiently to improve cancer care. Mirada's products are used
across diagnostic radiology, molecular imaging, radiation oncology,
medical oncology, tumour board and elsewhere. Mirada Medical was
originally spun out of the University of
Oxford. The company's technologies and products continue to
be developed by their team of specialists, engineers and
world-renowned scientists at Mirada's world headquarters in
Oxford, England. For more
information about Mirada Medical products visit:
http://www.mirada-medical.com.
For further information contact:
BTG plc
Chris Sampson, Corporate
Communications Director
+44-20-7575-1595; Mobile: +44-7773-251-178
Mirada Medical Ltd
Annamaria Albano, Marketing
Programmes Manager
+44-1865-261-410
Annamaria.albano@mirada-medical.com
Media Liaison
Jonathan Kearney
+44-20-8618-2755; Mobile: +44-7725-925-841
References:
- Pellerin O, et al. Cancer Biother Radiopharm
2013;28(6):459-65.
SOURCE BTG plc